LINQURE
LIVE

Serial Number

90736220

Owner

UNIQURE IP B.V.

Attorney

Julianne Abelman

Filing Date

May 26, 2021

Add to watchlist:

No watchlists yet
View on USPTO

LINQURE Trademark

Serial Number: 90736220 • Registration: 7376828

LINQURE is a trademark filed by UNIQURE IP B.V. on May 26, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

UNIQURE IP B.V. (20 trademarks)

MEIBERGDREEF 61
AMSTERDAM 1105BA , NL

Entity Type: 99

uniQure biopharma B.V. (17 trademarks)

Paasheuvelweg 25
Amsterdam 1105BP , NL

Entity Type: 26

Trademark Details

Filing Date

May 26, 2021

Registration Date

May 7, 2024

Published for Opposition

July 19, 2022

Goods & Services

Medicinal preparations for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases, namely, viral systems, gene therapy systems, nucleic acid delivery systems, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors; Viral systems, gene therapy systems, nucleic acid delivery systems for medical purposes, namely, medicines for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases; clinical medical reagents for use in nucleic acid based therapy, gene therapy, cell therapy, gene diagnosis and gene testing

Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; Consultancy in the field of pharmaceutics, namely, pharmaceutics in the field of gene therapy

Research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; Research and product development in the field of pharmaceutics, namely, pharmaceutics in the field of gene therapy

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jun 11, 2025 ASGN
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jun 4, 2025 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 4, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jun 4, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 4, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 4, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 4, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 4, 2025 COAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 7, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
May 7, 2024 R.PR
POST PUBLICATION AMENDMENT - ENTERED
Jan 27, 2023 CHPB
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jan 26, 2023 ETOP
ASSIGNED TO PETITION STAFF
Jan 25, 2023 APET
TEAS POST PUBLICATION AMENDMENT RECEIVED
Jan 12, 2023 EPPA
EXTENSION OF TIME TO OPPOSE RECEIVED
Aug 18, 2022 ETOF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 20, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jul 20, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 20, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 20, 2022 REAP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 19, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jul 19, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 29, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 13, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 31, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 31, 2022 CRFA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 31, 2022 CHAN
ASSIGNED TO LIE
May 28, 2022 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 22, 2022 ERSI
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 22, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
May 22, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 22, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 22, 2022 REAP
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 10, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 10, 2022 GNSL
SUSPENSION LETTER WRITTEN
Feb 10, 2022 CNSL
ASSIGNED TO EXAMINER
Feb 8, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 20, 2021 NWOS
NEW APPLICATION ENTERED
May 29, 2021 NWAP